The Pharma Data

DECEMBER 4, 2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).

Immune Response 52

Immune Response Vaccine Hospitals Laboratories 52

Broad Institute

JANUARY 19, 2024

By examining the genomes of bacteria collected from hundreds of people with persistent Salmonella infections, they discovered genetic mutations that both reduce the bacteria’s “virulence,” or ability to infect, and dampen the host’s immune responses, creating a kind of molecular camouflage that shields the bacteria from the immune system’s gaze.

Immune Response 119

Immune Response Treatment Disease Research 119

Drug Target Review

NOVEMBER 24, 2023

1 Dr Ninh (Irene) La-Beck, from the Department of Immunotherapeutics and Biotechnology at the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. The grant will enable her to investigate the interaction of nanoparticles with the immune system and cancer, supporting the development of new drug delivery systems.

Immune Response 111

Immune Response Pharmacy Treatment Virus 111

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study. Sanofi, Empowering Life.

Immune Response 52

Immune Response Vaccine Trials Treatment 52

Drug Target Review

DECEMBER 27, 2023

This interaction inhibits inflammation and immune activation, and in particular prevents macrophages from phagocytosing and destroying cancer cells. By blocking CD24 with an antibody drug, our goal is to powerfully reactivate the anti-cancer immune response and drive therapeutic efficacy.

Immune Response 105

Immune Response Science Clinical Development Drugs 105

Drug Target Review

OCTOBER 19, 2023

Their research centres around a remarkable immune protein called IL-31, which not only induces itching but also plays a crucial role in regulating inflammation. It’s the first time they have seen the nervous system directly tamp down an allergic response.

Immune Response 104

Immune Response Regulations Treatment Therapies 104

PLOS: DNA Science

FEBRUARY 8, 2024

The molecular tools of CRISPR were borrowed and developed from the natural immune response of bacteria to viruses – bacteriophages – that infect them. CRISPR may make sense for replacing a single mutant gene, like the one behind sickle cell disease, for which a CRISPR-based gene therapy was recently approved.

Immune Response 97

Immune Response DNA Engineering Virus 97

Drug Target Review

NOVEMBER 6, 2023

Advances in disease understanding and combination strategies in haematology We now know that blood cancers are characterised by molecular and phenotypic heterogeneity. 2 It is this complexity that necessitates powerful, targeted combination therapies.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . The agreement encompasses Lead Pharma’s entire pipeline.

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

DrugBank

MAY 15, 2024

This method was more about serendipity than science. Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. But as molecular biology has advanced, so too has our approach to finding new drugs.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

Drug Target Review

APRIL 7, 2025

The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

PLOS: DNA Science

OCTOBER 19, 2023

Last week DNA Science covered a setback in a clinical trial of a gene therapy for Duchenne muscular dystrophy (DMD). Also recently, FDA’s Cellular, Tissue, and Gene Therapies Advisory Committe turned down a stem cell treatment for amyotrophic lateral sclerosis, aka ALS, Lou Gehrig’s disease, or motor neuron disease.

Therapies 105

Therapies FDA Clinical Trials Disease 105

The Pharma Data

NOVEMBER 10, 2020

. P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease. Crohn’s Disease Therapeutics Market Size $4.7 Oral and nasal administration routes are both physiologic approaches to stimulate the mucosal immune system to induce disease modifying benefits.”.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

The Pharma Data

JANUARY 31, 2021

–( BUSINESS WIRE )– Gilead Sciences, Inc. While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. 1, 2021 11:00 UTC. FOSTER CITY, Calif. &

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

Drug Target Review

JUNE 9, 2023

C ould you explain the specific mechanisms or techniques used in the pre-clinical research to translate the genetics of the adaptive immune system into clinical products for disease detection and treatment? What types of diseases or conditions were targeted in the pre-clinical research phase? a healthcare informatics company.

Treatment 106

Treatment Packaging Clinical Research Therapies 106

The Pharma Data

APRIL 15, 2022

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. About BioNTech.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. Autoimmune diseases affect more than 24 million people in the U.S.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

DECEMBER 8, 2020

With the proceeds, Qu Biologics will complete stage 1 of the RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease and its Phase 2 Study to assess activation of anti-cancer immune response in colon cancer. “We

Immune Response 52

Immune Response Clinical Trials Disease Trials 52

Broad Institute

FEBRUARY 11, 2025

By exploring the landscape of B cell states in tumors, and the mechanisms by which B cells control tumor growth, they hope to learn how to harness anti-tumor immune responses for treatment more effectively. Learn more about the Broad Discovery Series.

Medical Schools 52

Medical Schools Immune Response Hospitals Doctors 52

Drug Target Review

APRIL 3, 2024

Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. Communication and networking are key in any career, with science being no exception.

Science 106

Science Clinical Development Treatment DNA 106

Broad Institute

JULY 26, 2022

Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. It gets its name from the intestinal mucus it breaks down.

Research 52

Research Immune Response Medical Schools Disease 52

Olympian Clinical Research

MAY 6, 2024

These targeted therapies revolutionized treatment, offering relief to severe cases by specifically addressing the underlying immune responses causing the disease. Learn more about the new and upcoming studies that might not only offer direct benefits but also contribute to the global fight against this complex disease.

Treatment 52

Treatment Small Molecule Clinical Research Immune Response 52

Broad Institute

JUNE 14, 2023

Glimcher is a member of the National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, a member of the American Philosophical Society, a member of the National Academy of Medicine, and the former president of the American Association of Immunologists. She has also received the 2017 George M.

Medical Schools 52

Medical Schools Immune Response Science Hospitals 52

Drug Target Review

SEPTEMBER 8, 2023

Remarkably, these findings propose that the presence of a cytoplasmic version of RARα is indispensable for T cells to initiate their defence against diseases. Importantly, this phenomenon’s silver lining is that RA’s interference with cytoplasmic RARα curbs the T cell’s inflammatory response.

Regulations 98

Regulations Research DNA Immune Response 98

Drug Target Review

FEBRUARY 28, 2024

from 2003 to 2006, covering the biotechnology and life-science tools sectors. Earlier in his career, Mr Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. Human γδ TCR repertoires in health and disease.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Drug Target Review

OCTOBER 17, 2024

While its involvement in the do-not-eat-me signal from cancer has inspired therapeutic development of this pathway for oncology, the function of the innate immune checkpoint we identified in 2009 1 extends to both innate and adaptive immune responses. CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses.

Immune Response 52

Immune Response Clinical Trials Trials Therapies 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection. About Trimer-Tag © Technology.

Vaccine 52

Vaccine Immune Response Virus RNA 52

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

Science, 2020 One way to fight COVID-19 is with drugs that directly target SARS-CoV-2, the novel coronavirus that causes the disease. The goal, as reported in the journal Science , was to use these protein “interactomes” to uncover vulnerabilities shared by all three coronaviruses. Credit: DE Gordon et al., Gordon DE et al.

Drug Development 52

Drug Development Drugs Virus Science 52

The Pharma Data

OCTOBER 9, 2021

“While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases. About Ulcerative Colitis.

Disease 52

Disease Trials Science Immune Response 52

The Pharma Data

OCTOBER 23, 2020

In this week’s update, Pharma IQ share updates from WHO’s solidarity clinical trial and a new treatment option in Europe to help clinicians receive a better understand the Covid-19 patient immune response. We will continue to pursue the science behind this,” Dr. Jalkanen added.

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

DECEMBER 11, 2020

“They will be asked to stand in line and get a vaccine also,” said Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center in Nashville, Tenn. ” Coronaviruses are notorious for prompting a flawed and incomplete immune response in humans, infectious disease experts say. .

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. The research was published online recently in Proceedings of the National Academy of Sciences.

Immune Response 52

Immune Response Virus Engineering Disease 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. GSK’s response to COVID-19 has been one of the broadest in the industry, with two potential treatments in addition to our vaccine candidates in development. GSK commitment to tackling COVID-19.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

MAY 15, 2023

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera Gilead Sciences, Inc. Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

JULY 6, 2021

PGRN is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new immuno-neurology treatments. The companies will be jointly responsible for commercialisation in the U.S. Outside the U.S.,

Disease 52

Disease Science Treatment Clinical Development 52

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S. About BioNTech.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52